Luke Gammon

Multiplexed Immunofluorescence Assay for Spatial Assessment of Senescence Markers in vivo

Ryan Wallis, Federica Mossa, Metka Gorkic Casey, Luke Gammon et autres

Multiplexed immunofluorescence (IF) staining represents a step-change in sophistication over traditional IF imaging allowing sequential detection of multiple antibody markers within a single tissue section. This facilitates profiling of a wider range of cell types and tissue structures, as well as allowing …

gb (code pays fourni par la source)

Patient-derived extracellular matrix scaffolds enable physiologically relevant ex vivo models of vulvar cancer

Rammah Elnour, Harsh Dongre, Lorena Larios Salazar, Christiane Helgestad Gjerde et autres

no, gb (code pays fourni par la source)

SAMP-Score: a morphology-based machine learning classification method for screening pro-senescence compounds in p16 positive cancer cells

Ryan Wallis, Bethany K. Hughes, Madeleine H. Moore, Emily A. O’Sullivan et autres

BACKGROUND: Senescence identification is rendered challenging due to a lack of universally available biomarkers. This represents a bottleneck in efforts to develop pro-senescence therapeutics - agents designed to induce the arrest of cellular proliferation associated with a senescence response in cancer cells …

gb (code pays fourni par la source)

A CD24+CD271+ melanoma cancer stem cell possesses hybrid characteristics of its single marker counterparts and promotes invasion and therapeutic resistance

Olivia Knowles, Patricio Doldan, Isabella Hillier-Richardson, Sophia Lunetto et autres

Abstract Background An important role for phenotype switching has been demonstrated in metastasis and therapeutic resistance of both melanoma and epithelial tumours. Phenotype switching in epithelial tumours is driven by a minority cancer stem cell (CSC) sub-population with lineage plasticity, but such …

gb (code pays fourni par la source)

SAMP-Score: A morphology-based machine learning classification method for screening pro-senescence compounds in p16 positive cancer cells

Ryan Wallis, Bethany K. Hughes, Madeleine H. Moore, Emily A. O’Sullivan et autres

Abstract Background Senescence identification is rendered challenging due to a lack of universally available biomarkers. This represents a bottleneck in efforts to develop pro-senescence therapeutics – agents designed to induce the arrest of cellular proliferation associated with a senescence response in cancer …

gb (code pays fourni par la source)

Disseminating cells in human oral tumours possess an EMT cancer stem cell marker profile that is predictive of metastasis in image-based machine learning

Gehad Youssef, Luke Gammon, Leah Ambler, Sophia Lunetto et autres

Cancer stem cells (CSCs) undergo epithelial-mesenchymal transition (EMT) to drive metastatic dissemination in experimental cancer models. However, tumour cells undergoing EMT have not been observed disseminating into the tissue surrounding human tumour specimens, leaving the relevance to human cancer uncertain. We have …

gb (code pays fourni par la source)

Author response: Disseminating cells in human oral tumours possess an EMT cancer stem cell marker profile that is predictive of metastasis in image-based machine learning

Gehad Youssef, Luke Gammon, Leah Ambler, Sophia Lunetto et autres

Cancer stem cells that have undergone EMT are identified in the region surrounding metastatic human oral tumours in a retrospective cohort study, and these are predictive of metastatic outcome in an image-based machine learning approach.

gb (code pays fourni par la source)

Dose imbalance of DYRK1A kinase causes systemic progeroid status in Down syndrome by increasing the un-repaired DNA damage and reducing LaminB1 levels

Aoife Murray, Gillian Gough, Ana Cindrić, Frano Vučković et autres

BACKGROUND: People with Down syndrome (DS) show clinical signs of accelerated ageing. Causative mechanisms remain unknown and hypotheses range from the (essentially untreatable) amplified-chromosomal-instability explanation, to potential actions of individual supernumerary chromosome-21 genes. The latter explanation could open a route to therapeutic …

gb, sg, hr, us, it, es, ru (code pays fourni par la source)

A CD24 + CD271 + Melanoma Cancer Stem Cell Possesses Hybrid Characteristics of its Single Marker Counterparts and Promotes Invasion and Therapeutic Resistance

Olivia Knowles, Patricio Doldan, Isabella Hillier-Richardson, Stephanie Lunt et autres

Abstract An important role for phenotype switching has been demonstrated in metastasis and therapeutic resistance of both melanoma and epithelial tumours. Phenotype switching in epithelial tumours is driven by a minority cancer stem cell sub-population with lineage plasticity, but such a sub-population …

gb (code pays fourni par la source)

Supplementary Figures S1, S2, S3, S4, S5 from Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma

Ankit Bharat Patel, Lucía Fraile García, Viviana Mannella, Luke Gammon et autres

Supplemental Information includes 5 Supplementary figures and legends: Figure S1: Correlation of p63 expression and BRAF/NRAS mutational status in melanoma and characterization of MAPKi resistant melanoma cell lines. Figure S2: p63 upregulation in MAPKi resistant melanoma. Figure S3: ITCH and FBXW7 expression …

Supplementary Figures S1, S2, S3, S4, S5 from Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma

Ankit Bharat Patel, Lucía Fraile García, Viviana Mannella, Luke Gammon et autres

Supplemental Information includes 5 Supplementary figures and legends: Figure S1: Correlation of p63 expression and BRAF/NRAS mutational status in melanoma and characterization of MAPKi resistant melanoma cell lines. Figure S2: p63 upregulation in MAPKi resistant melanoma. Figure S3: ITCH and FBXW7 expression …

Data from Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma

Ankit A. Patel, Lucía Fraile García, Viviana Mannella, Luke Gammon et autres

Abstract Targeting the MAPK pathway by combined inhibition of BRAF and MEK has increased overall survival in advanced BRAF-mutant melanoma in both therapeutic and adjuvant clinical settings. However, a significant proportion of tumors develop acquired resistance, leading to treatment failure. We have …